Current opinion in oncology · 2026
Recent developments and outstanding challenges in germ cell tumors.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Khalid Ahmed Bilal, Salous Tareq
Аннотация
PURPOSE OF REVIEW: Remaining challenges in management of patients with germ cell tumors (GCTs) include selecting the optimal treatment modality in patients with early metastatic disease, biomarker development and developing newer treatments in patients with refractory disease. This review aims to highlight recent developments in these domains.
RECENT FINDINGS: For patients with testicular seminoma with low-volume retroperitoneal lymphadenopathy, retroperitoneal lymph node dissection is a viable treatment option. Novel biomarkers showing promise in patients with GCTs include circulating tumor DNA and microRNA 371; with further validation from larger prospective studies, these may be useful in clinical decision making in patients with GCTs. Claudin 6's ubiquitous expression in testicular GCTs has enabled the development of several ongoing clinical trials targeting it and these therapies may be promising in treating patients with refractory GCTs.
SUMMARY: Management of patients with GCT requires a multidisciplinary approach and patients with advanced disease being considered for surgery or those with refractory disease should be referred to a high-volume treatment center. Outcomes in refractory GCT remain poor, but several novel treatment options and approaches are being explored in clinical trials to improve cure rates in this patient population.
RECENT FINDINGS: For patients with testicular seminoma with low-volume retroperitoneal lymphadenopathy, retroperitoneal lymph node dissection is a viable treatment option. Novel biomarkers showing promise in patients with GCTs include circulating tumor DNA and microRNA 371; with further validation from larger prospective studies, these may be useful in clinical decision making in patients with GCTs. Claudin 6's ubiquitous expression in testicular GCTs has enabled the development of several ongoing clinical trials targeting it and these therapies may be promising in treating patients with refractory GCTs.
SUMMARY: Management of patients with GCT requires a multidisciplinary approach and patients with advanced disease being considered for surgery or those with refractory disease should be referred to a high-volume treatment center. Outcomes in refractory GCT remain poor, but several novel treatment options and approaches are being explored in clinical trials to improve cure rates in this patient population.